Biography
Robert Augustin is a biochemist by training with 15 plus years of international experience in cardiometabolic research in academia and industry leading people, teams, projects, and collaborations.
Before joining the Business Development and Licensing organization at Boehringer Ingelheim in 2023, Robert worked in Cardiorenalmetabolic research, Translational Medicine, Project Management and Non-clinical Development at Boehringer Ingelheim and in the GLP-1 biology at Novo Nordisk.
As a drug discovery professional, he comes with a track record to deliver clinical stage assets – e.g. the GCGR/GLP-1R dual agonist survodutide, the NPY2R agonist BI 1820237, and the novel first-in class triple agonist BI 3034701, peptide hormone mimetics for the treatment of people with obesity and cardiorenalmetabolic diseases.
Topic
From GLP-1 to Nutrient-Stimulated Polyagonists: from T2D to Obesity to Cardiorenalmetabolism and Beyond
The evolution from GLP-1 agonists to multi-target peptide therapies is transforming treatment for type 2 diabetes, obesity, and cardiorenalmetabolic diseases. Survodutide and the NPY2R agonist BI 1820237 serve as illustrative examples of clinical progress in this field. A perspective on future directions and next-generation targets will be provided.